Moderna (MRNA) cancer vaccine trial shows positive early results
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowIn its first late-stage trial, a personalized cancer vaccine from Moderna (MRNA) and Merck showed positive results. The trial involved over 1,100 patients with higher-risk melanoma and met key goals, significantly extending time until cancer recurrence compared to Keytruda alone. Following the announcement, Merck's stock rose over 8% and Moderna's shares soared about 100%. The trial's success suggests that this combination could be a significant new treatment option for melanoma, impacting future drug development and potential market dynamics for these companies.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Moderna Inc. (MRNA)
Moderna is a biotech pioneering mRNA vaccines and therapeutics.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRNA news
- Premarket Stock Moves: Zillow, Peloton, Sandisk, Moderna Update
- Apple (AAPL) and other Stocks Showing Notable Premarket Moves
- Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
- Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
- Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
